Immunotherapy for Merkel Cell Carcinoma — Why This Rare Skin Cancer Responds

Most people diagnosed with Merkel cell carcinoma are not candidates for immunotherapy. The majority of cases are found while the tumour is still confined to the skin and the nearby lymph nodes. The established treatment there is surgery, usually followed by radiotherapy, and immunotherapy is not part of standard practice in that setting.

Whether immunotherapy given after surgery lowers the risk of the disease returning is an open question. It has been studied in trials, it is not established practice as of August 2026, and being offered it in that setting is a reason to ask which trial or which guidance the recommendation rests on.

Immunotherapy is for advanced disease. That means Merkel cell carcinoma that has spread beyond the original site and regional nodes, or disease that is locally advanced and cannot be removed by surgery. In those situations a checkpoint inhibitor is the recognised first systemic treatment, ahead of chemotherapy.

There is a second restriction, and in this particular cancer it is a painful one. A meaningful share of Merkel cell carcinoma occurs in people whose immune system is already suppressed — organ transplant recipients on anti-rejection drugs, people with chronic lymphocytic leukaemia, people living with HIV. Weakened immune surveillance is part of why the tumour developed. Those same patients were largely excluded from the trials that established checkpoint inhibitors here, and in transplant recipients there is a genuine risk that releasing the immune brake triggers rejection of the transplanted organ.

So the evidence is thinnest exactly where the disease is most concentrated. That does not automatically rule anyone out. It means the decision in an immunosuppressed patient is an individual one, taken jointly with the transplant or haematology team, with the risks named out loud rather than glossed over.

Active autoimmune disease and ongoing high-dose steroid treatment carry the usual cautions that apply to any checkpoint inhibitor.

Nothing on this page decides eligibility. That rests on the biopsy report, the stage, your immune status and overall fitness, read together by a medical oncologist.

Because there is an unusual amount for the immune system to recognise. Checkpoint inhibitors do not attack a tumour directly. They release a brake on immune cells so those cells can act on something they already see as foreign. How well that works depends almost entirely on how visible the tumour is. Merkel cell carcinoma is one of the most visible there is.

It gets there by two completely different routes, and roughly speaking every case takes one of them.

The first route is viral. About four out of five Merkel cell carcinomas carry Merkel cell polyomavirus, a common virus that is harmless in almost everyone who has it. In these tumours, the viral genetic material has integrated into the tumour cell and the cell continuously produces viral proteins. Those proteins are not human. There is no ambiguity about them at all, which is exactly the condition under which released immune cells do their best work.

The second route is ultraviolet damage. The remaining cases are virus-negative and arise on sun-damaged skin in older adults. They carry one of the highest mutation burdens recorded in any cancer — years of accumulated ultraviolet injury, each error capable of producing an abnormal protein that immune cells can flag as wrong.

The comparison that makes this concrete is with acral melanoma, the melanoma subtype most common in India, which is neither virus-driven nor ultraviolet-driven. It carries a low mutation load and, correspondingly, responds to checkpoint inhibitors less often. Merkel cell carcinoma sits at the opposite end of the same spectrum. Same drugs, same mechanism, very different amount of raw material to work with.

This is also why chemotherapy, which is not short of activity in Merkel cell carcinoma, is no longer the first systemic treatment. It shrinks these tumours in a large proportion of patients, but the control it achieves is typically brief. Immunotherapy trades a somewhat different chance of response for the possibility of one that holds.

Read down the first column until you find the situation described on your report. Most people stop in the first two rows.

Pathway summarised from NCCN Merkel cell carcinoma guidance current as of August 2026. No survival figure is quoted anywhere on this page. Merkel cell carcinoma is rare enough that survival numbers circulating online are frequently drawn from small or outdated series.

Higher than in most cancers, and lasting longer when it happens — but not in everyone, and not permanently. Published reviews of first-line checkpoint inhibitor trials in advanced Merkel cell carcinoma report objective response rates in the region of half of patients, with measurable disease disappearing entirely in a smaller subset. Where immunotherapy is given after chemotherapy has already failed, the reported response rate is lower, around a third.

Those are ranges summarised from NCCN Merkel cell carcinoma guidance and published trial reviews current as of August 2026. They were generated in trial populations that were selected, were mostly not Indian, and largely excluded immunosuppressed patients. Treat them as a description of what has been observed, not as a prediction about you.

Duration is the part that makes this cancer different. Where a response does occur, follow-up reports describe control that often persists for years rather than months, and that can continue after treatment has stopped. That is the behaviour of an established immune response rather than of a drug holding a tumour down.

A long response is not the same as the disease being gone for good. This distinction is worth stating plainly, because Merkel cell carcinoma is the cancer where it is most often blurred. Some patients do relapse after a durable response, sometimes years later, which is why follow-up scanning continues even when everything looks clear. Anyone who tells you the disease has been permanently eliminated is going beyond what the published follow-up supports.

Two practical points about timing. Responses are not always immediate, and a first assessment scan can look worse before it looks better as immune cells flood into the tumour — a pattern your oncologist will interpret alongside how you actually feel. And roughly half of patients do not respond at all, in which case the plan moves on rather than waiting.

At CION, immunotherapy is administered as day care at our centres. Response-assessment CT and PET-CT imaging is coordinated at partner imaging centres rather than performed in-house.

Chemotherapy and radiotherapy both remain genuinely useful in Merkel cell carcinoma, which is not true of every cancer. This is a reassuring page to be able to write, and it matters most for the immunosuppressed patients who may not be able to have a checkpoint inhibitor safely.

Chemotherapy shrinks Merkel cell carcinoma in a large proportion of patients. Its weakness is durability rather than activity: the control it achieves is typically short, often measured in months, and the disease tends to return. That is precisely why immunotherapy displaced it as the first systemic treatment, and it is also why it remains a sensible option when immunotherapy is unsuitable or has stopped working.

Radiotherapy deserves more attention than it usually gets here. Merkel cell carcinoma is markedly sensitive to radiation, so a single symptomatic site — a painful deposit, a lump that is threatening the skin surface — can often be controlled quickly and with a modest number of sessions. It is used alongside systemic treatment, not only instead of it.

For a transplant recipient, the decision is a trade between two risks: the risk of the cancer progressing, and the risk of losing a transplanted organ. Some teams reduce immunosuppression, some switch the class of anti-rejection drug, some choose chemotherapy or radiotherapy to avoid the question. There is no single correct answer, and the discussion belongs jointly to the oncology and transplant teams.

Clinical trials in Merkel cell carcinoma are active internationally and are worth asking about. This page is informational: it can explain that trials exist and how to ask about them, and it cannot promise anyone a place in one.

• Is this advanced disease, or disease that has been fully removed? The answer decides whether immunotherapy belongs in the conversation at all. Use after complete surgery is still being studied and is not established practice.
• Has your immune status been discussed? A transplant, chronic lymphocytic leukaemia or HIV changes both the risk and the strength of the evidence behind the recommendation. It should be raised by the team, not discovered later.
• What is the plan if the first assessment scan is disappointing? Ask at the start. Knowing that chemotherapy and radiotherapy both remain useful here makes the first decision easier to take, not harder.
• Who do you call, and at what hour, if a side effect starts? Immune-related inflammation of the bowel, lungs, liver or hormone glands can begin weeks or months in, including after treatment ends. Get the number before the first cycle.
• What does follow-up look like if the response is good? Scanning continues even when everything looks clear, because a durable response is not a permanent removal of the disease. Knowing that in advance prevents an unpleasant surprise later.

• Hodgkin lymphoma is the other cancer where checkpoint inhibitors work with unusual consistency, and for a related reason — Immunotherapy for Hodgkin Lymphoma explains what makes those tumour cells so exposed.
• The picture is far more mixed once you leave Hodgkin disease behind — Immunotherapy for Non-Hodgkin Lymphoma sets out where checkpoint inhibitors help and where they do not.
• Checkpoint inhibitors were not the first immunotherapy, and in blood cancers they were not even the most important — Antibody Therapy for Blood Cancers: The Original Immunotherapy covers the approach that came decades earlier and still does the heavy lifting.
• For how immunotherapy is delivered, monitored and paid for across our centres, see Immunotherapy at CION Cancer Clinics.

Unsure how any of this applies to a specific report? Book a free consultation and a medical oncologist will read it with you.